mRNA technology Archives

moderna biontech personalized cancer vaccine

News and Trends 15 Nov 2017

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CureVac Moderna Therapeutics Biotech Unicorn Battle mRNA

Interview 6 Nov 2017

Battle of the Biotech Unicorns: CureVac vs. Moderna

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

November 6, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […]

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 26 Sep 2017

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […]

September 26, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 25 Sep 2017

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […]

September 25, 2017 - 1 minutemin - By Alex Dale

Astrazeneca Ethris mRNA Therapy MedImmune Edited

News and Trends 21 Aug 2017

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA technology to develop treatments for respiratory disease. Ethris, located in the Munich biotech hub of Martinsried, has attracted the attention of AstraZeneca with its mRNA platform despite still being in an early development stage. The big pharma will pay Ethris €25M […]

August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CureVac mrna vaccine rabies Ingmar Hoerr

News and Trends 26 Jul 2017

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door for a new generation of better and cheaper vaccines. CureVac, based in Tübingen, Germany, is a pioneer in the development of therapeutic mRNA technology. The company has published today in The Lancet proof-of-concept data from a Phase I trial testing CV7201, […]

July 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

universal cancer vaccine mrna biontech personalized medicine

News and Trends 5 Jul 2017

Results are in from the First Human Trial of an Universal Cancer Vaccine

BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with the potential to target all cancer types. Published in Nature, the results from the first trial in humans with a personalized mRNA cancer vaccine hint that BioNTech is on a promising track towards the development of a universal cancer vaccine. All […]

July 5, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Interview 3 Jul 2017

Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech

Sean Marett took a red-eye from New York to speak at Refresh last month: here are his thoughts on how mRNA therapeutics are taking biotech by storm! mRNA has become one of the next big things in biotech, and Germany-based BioNTech is at the forefront of the wave, developing personalized treatments for cancer. “We try to provide individualized […]

July 3, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 30 Jun 2017

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […]

June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jun 2017

BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies

BioNTech has reported a new technology that could overcome some of the most challenging issues of antibody production by encoding them into mRNA drugs. BioNTech, one of the most advanced companies in the mRNA therapeutics field, has reported preclinical data for a new class of mRNA drugs that instruct the body to create its own […]

June 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

mRNA technology

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Battle of the Biotech Unicorns: CureVac vs. Moderna

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

Results are in from the First Human Trial of an Universal Cancer Vaccine

Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!